Outset Medical Q3 revenue $27.8M (+5.5% YoY); raises 2022 guidance to $111-113M

Outset Medical, Inc.

2022-Q3 EPS reported -$2.54 revenue$83,368,000

Revenue $27.8M, +5.5% YoY and +10.8% QoQ; gross margin 15.6% vs 11.2% YoY.
Net loss ($40.8M) / ($0.85) per share; non-GAAP EPS ($0.70).
Raises FY2022 revenue guidance to $111M-$113M from $105M-$110M.
Awarded 5-year VA contract for Tablo at 106 VA hospitals and home settings.
Secured up to $300M in debt financing to strengthen balance sheet.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Outset Medical, Inc. reported the third quarter ended September 30, 2022 results: revenue $27.8 million, net income ($40.8) million, EPS ($0.85) per share. Guidance raised.

Period: the third quarter ended September 30, 2022
Revenue: $27.8 million
Net income: ($40.8) million
EPS: ($0.85) per share
Guidance: raised
Result: reported results

Exact text from the filing

specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million San Jose, CA – November 8, 2022 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Outset Medical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023229

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.